April 5, 2017

Valneva's Lyme disease 
Vaccine candidate - VLA15

Valneva has developed a multivalent, protein subunit based vaccine candidate against Lyme disease.

In December 2016, Valneva initiated a Phase I trial in the US and Europe, following clearance from the Food & Drug Administration (FDA) and the Belgian authorities, that will include 180 subjects. The first patient was vaccinated at the end of January 2017.

Pre-clinical data showed that this vaccine candidate can provide protection against the majority of Borrelia species pathogenic for humans (Source).

In 2017, the company will advance the Phase I trial of its Lyme vaccine candidate and expects to accelerate the program´s progression towards Phase II.

Valneva’s program is the only active vaccine development program for Lyme disease in the pharmaceutical industry.


About Lyme borreliosis

This program is supported by the Vienna Business Agency.

Link Here-

hits counter